Research Article
Timing of Radiation Pneumonitis in Patients with Stage 3 Non-Small-Cell Lung Cancer Receiving Consolidation Durvalumab after Chemoradiation
Table 1
Patient and clinical characteristics.
| Number of patients | N = 31 |
| Age (years) | Median (range) | 67 (41, 87) | Gender | Female | 14 (45.2) | Male | 17 (54.8) | EGFR (for adenocarcinoma or NOS histology) | Negative | 14 (45.2) | Positive | 7 (22.6) | Unknown | 10 (32.2) | ALK | Negative | 18 (58.1) | Positive | 3 (9.7) | Unknown | 10 (32.2) | PDL1 | <1% | 0 | 1–49% | 23 (74.2) | >50% | 8 (25.8) | Stage | Stage 3a | 16 (51.6) | Stage 3b | 14 (45.2) | Stage 3c | 1 (3.2) | Durvalumab | Yes | 12 (39) | No | 19 (61) | Concurrent chemotherapy | No | 5 (16) | Yes | 26 (84) | Type of chemotherapy | Cisplatin and etoposide | 11 (35.5) | Cisplatin and pemetrexed | 7 (22.6) | Carboplatin and paclitaxel | 6 (19.4) | Carboplatin and pemetrexed | 2 (6.5) | No chemo | 5 (16) | Prescription dose | 66 Gy in 33 | 13 (41.9) | 60 Gy in 30 | 18 (58.1) | Completed prescribed dose | Yes | 31 (100) | Mean lung dose Gy, mean (SD) | 15.8 (1.56) | V5Gy, %, mean (SD) | 60.14 (2.73) | V20Gy, %, mean (SD) | 29.96 (1.82) |
|
|
EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; NOS, not otherwise specified; SD, standard deviation.
|